Related Experiment Video
Updated: Aug 29, 2026
Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
Pediatric cystic fibrosis: evaluating costs and genetic testing
Warren Balinsky1, Carolyn W Zhu
1Milano Graduate School of Management and Urban Policy, New School University, New York, NY, USA. wbalinsk@newschool.edu
Insights
This review examines pediatric cystic fibrosis, focusing on genetic testing and associated costs. Early genetic screening and education for healthcare professionals are recommended to improve outcomes for this common fatal genetic disease.
Area of Science:
- Pediatric Health
- Medical Genetics
- Public Health Policy
Background:
- Cystic fibrosis is the most prevalent fatal genetic disorder in the United States.
- Recent advancements in genetic testing and guidelines necessitate a review of current practices.
- Understanding the economic impact is crucial for resource allocation and patient access.
Purpose of the Study:
- To systematically review literature on pediatric cystic fibrosis.
- To critically evaluate factors related to genetic testing and costs.
- To inform healthcare professionals and policymakers on this critical pediatric health issue.
Main Methods:
- Systematic literature review of scientific articles and data sources.
- Critical evaluation of existing research on cystic fibrosis prevalence, costs, and genetic testing.
- Synthesis of information from national health organizations and professional bodies.
Main Results:
- Genetic testing for cystic fibrosis has become more sophisticated and accessible.
- The costs associated with cystic fibrosis, including diagnosis and long-term care, are significant.
- There is a need for standardized guidelines and increased awareness regarding genetic testing.
Conclusions:
- Genetic screening for cystic fibrosis in pediatric populations is essential for early diagnosis and management.
- Enhanced educational initiatives for healthcare providers are crucial for effective implementation of genetic testing.
- Addressing the financial aspects of cystic fibrosis care and genetic testing is vital for equitable access and improved patient outcomes.
Abstract:
The purpose of this article is to present a systematic, critical review of literature and data sources pertaining to pediatric cystic fibrosis, emphasizing and evaluating factors of costs and genetic testing. Cystic fibrosis is the most common fatal genetic disease in the United States. Therefore, its cause, prevalence, cost, and prevention make it important for review. Furthermore, the recent National Institutes of Health Consensus Statement on Genetic Testing for Cystic Fibrosis, the laboratory standards and guidelines published by the American College of Medical Genetics, the American College of Obstetricians and Gynecologists, and the National Human Genome Research Institute, and the increasing interest in genetic testing make it timely to discuss this major pediatric health topic. A broad educational effort, particularly among health care professionals, and genetic screening are advocated.
Related Concept Videos
01:23Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
01:29Pharmacogenomics: Identification of New Drug Targets